Novavax (NVAX)
(Real Time Quote from BATS)
$8.58 USD
+0.02 (0.23%)
Updated Sep 17, 2025 12:08 PM ET
3-Hold of 5 3
B Value C Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NVAX 8.58 +0.02(0.23%)
Will NVAX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NVAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVAX
MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response
COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths
NVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Boyd Gaming and Shoe Carnival have been highlighted as Zacks Bull and Bear of the Day
FDA Approves Updated COVID-19 Vaccines but With Restrictions
Other News for NVAX
U.S. health insurers pledge continuing coverage of COVID shots ahead of ACIP meeting
Former CDC Director Monarez says RFK Jr. fired her for not following two directives
NVAX's price rises by 5.94% on September 16, though its technical setup remains stable.
Crossed Above 20 Day Moving Average appears for NVAX after 1.25% move
Five new members added to CDC vaccine advisory panel